Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy

키워드

참고문헌 (37)

1. Lin PL, "Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model", Arthritis Rheum, 62, pp.340~350 (2010)
2. Goekoop-Ruiterman YP, "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial", Arthritis Rheum, 58(2 Suppl), pp.S126~S135 (2008)
3. Heiberg MS, "The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study", Ann Rheum Dis, 66, pp.1038~1042 (2007)
4. Weaver AL, "The impact of new biologicals in the treatment of rheumatoid arthritis", Rheumatology (Oxford), 43(Suppl 3), pp.iii17~iii23 (2004)
5. Finckh A, "The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study", Arthritis Rheum, 54, pp.54~59 (2006)
6. Kornbluth A, "Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference", Inflamm Bowel Dis, 4, pp.328~329 (1998)
7. Keystone EC, "Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial", Arthritis Rheum, 50, pp.1400~1411 (2004)
8. Baraliakos X, "Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data", Arthritis Rheum, 53, pp.856~863 (2005)
9. Dixon WG, "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)", Ann Rheum Dis, 69, pp.522~528 (2010)
10. Marehbian J, "Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease", Am J Gastroenterol, 104, pp.2524~2533 (2009)
11. Tubach F, "Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry", Arthritis Rheum, 60, pp.1884~1894 (2009)
12. Genovese MC, "Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis", J Rheumatol, 32, pp.1232~1242 (2005)
13. Klareskog L, "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial", Lancet, 363, pp.675~681 (2004)
14. Maini RN, "Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate", Arthritis Rheum, 50, pp.1051~1065 (2004)
15. Grijalva CG, "Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases", JAMA, 306, pp.2331~2339 (2011)
16. Keystone EC, "Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 50, pp.353~363 (2004)
17. van de Putte LB, "Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed", Ann Rheum Dis, 63, pp.508~516 (2004)
18. 박재석, "결핵의 치료지침", 대한내과학회지, 82(3), pp.269~273 (2012), 대한내과학회
19. Im JG, "Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy", Radiology, 186, pp.653~660 (1993)
20. Malaviya AN, "Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report", J Rheumatol, 36, pp.1414~1420 (2009)
21. "Trend of case notification rate per 100,000 by year, 2004-2011"[URL]
22. Hong SJ, "Factors leading to under-reporting of tuberculosis in the private sector in Korea", INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 16(9), pp.1221~1227 (2012), INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
23. "Reported tuberculosis in the United States" (2011)[URL]
24. "Tuberculosis incidence rate per year per 100,000 population (upper bound)"[URL]
25. Sichletidis L, "Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis", Int J Tuberc Lung Dis, 10, pp.1127~1132 (2006)
26. "Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement", Am J Respir Crit Care Med, 161(4 Pt 2), pp.S221~S247 (2000)
27. Kisich KO, "Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils", Infect Immun, 70, pp.4591~4599 (2002)
28. Clay H, "Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death", Immunity, 29, pp.283~294 (2008)
29. Saunders BM, "T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection", Clin Exp Immunol, 137, pp.279~287 (2004)
30. Flynn JL, "Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice", Immunity, 2, pp.561~572 (1995)
31. Harris J, "Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis", J Infect Dis, 198, pp.1842~1850 (2008)
32. Algood HM, "TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection", J Immunol, 172, pp.6846~6857 (2004)
33. Zhou Z, "TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells", Cell Signal, 19, pp.1238~1248 (2007)
34. Keane J, "Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies", Curr Opin Rheumatol, 20, pp.443~449 (2008)
35. Dixon WG, "Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register", Arthritis Rheum, 54, pp.2368~2376 (2006)
36. Groves RW, "Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression", Br J Dermatol, 132, pp.345~352 (1995)
37. Vestergaard C, "Tumor necrosis factor-alpha-induced CTACK", CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB, 2005, pp.29, 49~55

관련 논문AI추천